Table 1

General presentation of the 10 patients with 'limited skin lupus' or toxiderma in a context of autoimmunity

Patient

Before anti-TNF alpha treatment

During onset of symptoms


Disease

Autoantibody

Clinical signs of lupus

Treatment

Duration of treatment (months)

Clinical signs of lupus

Biological signs of lupus


1

RA, erosive

RF+

None

ETA

36

Skin

ANA+, dsDNA+

2

RA, erosive

RF+

None

INF

6

Skin

ANA+, dsDNA+

3

RA, erosive

RF+, ANA+ 1:160°

None

INF

18

Skin

ANA+, dsDNA+

4

RA, erosive

RF-

None

ETA

5

Skin

ANA+, dsDNA+

5

RA, erosive

RF+

None

INF

7

Skin

ANA+, dsDNA+

6

RA erosive

RF+

None

ETA

5

Skin

ANA+, dsDNA+

7

RA, erosive

RF+

None

INF

11

Skin

ANA+, dsDNA+

8

RA, erosive

RF+

None

INF

3

Skin

ANA+, dsDNA+

9

RA, erosive

RF+

None

ETA

12

Skin

ANA+, dsDNA+

10

RA, erosive

RF+

None

INF

13

Skin

ANA+, dsDNA+


ANA, antinuclear antibodies; dsDNA, double-strand DNA; ETA, etanercept; INF, infliximab; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour necrosis factor; +, positive; -, negative.

De Bandt et al. Arthritis Research & Therapy 2005 7:R545-R551   doi:10.1186/ar1715

Open Data